Literature DB >> 10632677

Comparison of the suppressive effects of soluble CR1 and C5a receptor antagonist in acute arthritis induced in rats by blocking of CD59.

M Mizuno1, K Nishikawa, B P Morgan, S Matsuo.   

Abstract

We investigated the effects of suppression of complement activation at C3 level and inhibition of C5a on acute synovitis in rats. Acute synovitis was induced in Wistar rats by intra-articular (i.a.) injection into one knee of 0.3 mg of MoAb 6D1 (anti-rat CD59 antibody). In the treatment groups, soluble CR1 (sCR1) or C5a receptor (C5aR) antagonist was administered intra-articularly or intravenously and effects on the course of the acute synovitis were monitored. Synovitis induced by 6D1 was characterized by joint swelling, thickening of synovial tissue, cellular infiltration and deposition of membrane attack complex (MAC) on the synovial surface. Neither inflammatory change nor MAC deposition was found in rats which received an i.a. injection of sCR1 to suppress complement activity in the joint. Intra-articular injection of sCR1 did not reduce plasma complement activity. Intravenous administration of sCR1 suppressed plasma complement activity but had no effect on the course of the arthritis and synovitis with MAC deposition was observed. Neither i.a. nor i.v. injection of C5aR antagonist had any suppressive effects on inflammatory change or MAC deposition in synovium. The data show that inflammatory change induced by 6D1 was mediated by local complement activation and was not accompanied by systemic complement activation. C5a generation was not responsible for the observed inflammation, suggesting that other complement activation products, possibly MAC, mediate the inflammatory change observed in this model of acute synovitis in rats.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10632677      PMCID: PMC1905510          DOI: 10.1046/j.1365-2249.2000.01127.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

Review 1.  Therapeutic uses of recombinant complement receptors.

Authors:  B P Morgan; N K Rushmere; C L Harris
Journal:  Biochem Soc Trans       Date:  1998-02       Impact factor: 5.407

2.  [A method for quick decalcification].

Authors:  J PLANK; A RYCHLO
Journal:  Zentralbl Allg Pathol       Date:  1952-12-10

3.  The use of avidin-biotin interaction in immunoenzymatic techniques.

Authors:  J L Guesdon; T Ternynck; S Avrameas
Journal:  J Histochem Cytochem       Date:  1979-08       Impact factor: 2.479

4.  Stimulation of human rheumatoid synovial cells by non-lethal complement membrane attack.

Authors:  R H Daniels; W A Houston; M M Petersen; J D Williams; B D Williams; B P Morgan
Journal:  Immunology       Date:  1990-02       Impact factor: 7.397

5.  Purification of C8 and C9 from rat serum.

Authors:  J Jones; I Laffafian; B P Morgan
Journal:  Complement Inflamm       Date:  1990

6.  Recombinant soluble human complement receptor type 1 inhibits inflammation in the reversed passive arthus reaction in rats.

Authors:  C G Yeh; H C Marsh; G R Carson; L Berman; M F Concino; S M Scesney; R E Kuestner; R Skibbens; K A Donahue; S H Ip
Journal:  J Immunol       Date:  1991-01-01       Impact factor: 5.422

7.  Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis.

Authors:  H F Weisman; T Bartow; M K Leppo; H C Marsh; G R Carson; M F Concino; M P Boyle; K H Roux; M L Weisfeldt; D T Fearon
Journal:  Science       Date:  1990-07-13       Impact factor: 47.728

8.  Chronic arthritis of rabbits induced by mycoplasmas. II. Antibody response and the deposition of immune complexes.

Authors:  L R Washburn; B C Cole; J R Ward
Journal:  Arthritis Rheum       Date:  1980-07

9.  Increased urinary excretion of C5b-9 distinguishes passive Heymann nephritis in the rat.

Authors:  M Schulze; P J Baker; D T Perkinson; R J Johnson; R F Ochi; R A Stahl; W G Couser
Journal:  Kidney Int       Date:  1989-01       Impact factor: 10.612

View more
  6 in total

1.  Suppression of complement activation by recombinant Crry inhibits experimental autoimmune anterior uveitis (EAAU).

Authors:  Balasubramanian Manickam; Purushottam Jha; Natalie J Hepburn; B Paul Morgan; Claire L Harris; Puran S Bora; Nalini S Bora
Journal:  Mol Immunol       Date:  2010-09-16       Impact factor: 4.407

2.  Deficiency in complement C1q improves histological and functional locomotor outcome after spinal cord injury.

Authors:  Manuel D Galvan; Sabina Luchetti; Adrian M Burgos; Hal X Nguyen; Mitra J Hooshmand; Frank P T Hamers; Aileen J Anderson
Journal:  J Neurosci       Date:  2008-12-17       Impact factor: 6.167

Review 3.  Recent developments in low molecular weight complement inhibitors.

Authors:  Hongchang Qu; Daniel Ricklin; John D Lambris
Journal:  Mol Immunol       Date:  2009-10-02       Impact factor: 4.407

Review 4.  Tissue-targeted complement therapeutics.

Authors:  Stephen Tomlinson; Joshua M Thurman
Journal:  Mol Immunol       Date:  2018-07-07       Impact factor: 4.407

5.  A protein toxin from the sea anemone Phyllodiscus semoni targets the kidney and causes a severe renal injury with predominant glomerular endothelial damage.

Authors:  Masashi Mizuno; Masatoshi Nozaki; Nobuya Morine; Norihiko Suzuki; Kazuhiro Nishikawa; B Paul Morgan; Seiichi Matsuo
Journal:  Am J Pathol       Date:  2007-06-28       Impact factor: 4.307

Review 6.  Early Components of the Complement Classical Activation Pathway in Human Systemic Autoimmune Diseases.

Authors:  Katherine E Lintner; Yee Ling Wu; Yan Yang; Charles H Spencer; Georges Hauptmann; Lee A Hebert; John P Atkinson; C Yung Yu
Journal:  Front Immunol       Date:  2016-02-15       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.